Teva Pharmaceutical Industries’ (TEVA) late-stage study evaluating Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric and adolescent patients met its primary efficacy endpoint. The results demonstrated a statistically significant superior reduction in monthly migraine days over 12 weeks of treatment with Ajovy compared with placebo.Please note that Ajovy is already approved in several countries as a 225 mg once-monthly dose or a 675 mg once-quarterly dose, both administered as subcuta ...